Every 424B that Enanta Pharmaceuticals, Inc (ENTA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow ENTA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ENTA filings page.
Enanta Pharmaceuticals intends to offer and sell up to $75,000,000 of its common stock through an Open Market Sale (sales agreement) with Jefferies LLC as sales agent under an at-the-market offering structure. The sales agreement permits sales from time to time through Jefferies, which may receive commissions up to 3.0% of aggregate gross proceeds. The prospectus supplement uses an assumed offering price of $14.77 per share (the last reported sale price on July 1, 2026) to illustrate an aggregate issuance of 5,077,860 shares and presents illustrative dilution and as-adjusted net tangible book value. Shares outstanding are shown as 29,061,152 as of March 31, 2026. Sales may occur at varying prices and quantities; Jefferies is not required to sell any specific amount and will act using commercially reasonable efforts on mutually agreed terms.
Enanta Pharmaceuticals (ENTA) prospectus supplement describes a securities offering that would issue shares at $10.00 per share with aggregate proceeds shown as $65,000,000 (and an underwriting fee example of $0.60 per share or $3,900,000). Net proceeds are intended to fund clinical trials, research and development, working capital and general corporate purposes. The filing highlights ongoing revenue from an AbbVie collaboration and a 2023 royalty sale that help fund Enanta’s R&D programs. Clinical programs discussed include oral STAT6 inhibitors (a development candidate expected to be nominated in the second half of 2025), zelicapavir safety data showing mostly mild adverse events, and disease burdens for RSV and COVID-19 with specific hospitalization and mortality ranges for RSV in older adults. The supplement details a 60-day lock-up for insiders, exceptions (including Rule 10b5-1 plans), tax withholding rules for non-U.S. holders (generally 30% on dividends absent treaty relief), and references to incorporated reports and underwriting disclosures.
Enanta Pharmaceuticals (ENTA) prospectus supplement excerpts describe an offering with underwriter arrangements, lock-up agreements and planned use of proceeds to fund clinical trials, research and general corporate purposes. The company notes ongoing royalties from an AbbVie collaboration and proceeds from an April 2023 royalty sale that support its R&D programs.
The filing highlights clinical and preclinical programs including a STAT6 oral inhibitor program with a development candidate expected to be nominated in the second half of 2025, zelicapavir safety outcomes (mostly mild AEs; diarrhea 3.3%, asthma 2.5%) and antiviral efficacy signals versus placebo. The supplement also summarizes U.S. federal tax withholding rules for non-U.S. holders and customary risk and forward-looking statement disclaimers.